ABT

Abbott Laboratories 10-Q Summary: Period Ended June 30, 1999

Business Context and Reporting Period

This is an unaudited quarterly report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, covering the three and six months ended June 30, 1999. The company operates in six primary revenue segments: Pharmaceutical Products, Diagnostic Products, Hospital Products, Ross Products, International, and Chemical & Agricultural Products. As of July 31, 1999, the company had approximately 1.52 billion common shares outstanding.

Key Financial Metrics

Note: Debt figures represent the sum of short-term borrowings ($982.9M) and long-term debt ($1,337.6M) as of June 30, 1999.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 5.8% for the quarter and 7.0% for the six-month period compared to 1998. Excluding the negative impact of the stronger U.S. dollar, sales increased 6.8% and 7.5%, respectively.
• Earnings Growth: Net earnings rose 9.8% for the quarter and 11.4% for the six-month period. Diluted EPS increased 10.5% and 11.8%, respectively.
• Margin Compression: Gross profit margins declined to 56.5% (Q2) and 56.3% (YTD) from 57.7% and 57.8% in the prior year, attributed to unfavorable product mix, specifically lower pharmaceutical sales.
• Segment Performance:
  • Pharmaceuticals: Sales decreased 8.1% (Q2) and 5.9% (YTD) due to volume shortfalls of Abbokinase caused by FDA production issues.
  • Hospital Products: Sales increased 18.8% (Q2) and 15.9% (YTD).
  • Diagnostics: Sales increased 8.2% (Q2) and 11.1% (YTD).
• Liquidity: Short-term borrowings decreased by approximately $776 million since December 31, 1998, following the suspension of common stock repurchases.

Outlook, Risks, and Unusual Items

• Pending Acquisitions: Abbott announced definitive agreements to acquire ALZA Corporation (urology/oncology) and Perclose, Inc. (arterial closure devices). Both transactions are expected to close by year-end and be accounted for as a pooling of interests.
• Regulatory Issues (Abbokinase): The FDA suspended approval of Abbokinase production lots in late 1998 due to manufacturing concerns. While some lots were released in January 1999, new criteria were established in July 1999. No additional lots have been released, and future sales impact remains uncertain.
• Patent Litigation (Hytrin): An appellate court affirmed a lower court ruling that Abbott's patent for Hytrin (terazosin hydrochloride) is invalid. Generic competition is expected to begin in August 1999, which management believes will adversely impact sales. U.S. Hytrin sales dropped from $542 million in 1998 to $292 million in the first six months of 1999.
• Antitrust Litigation: Abbott is a defendant in numerous antitrust suits regarding prescription drug pricing. While settlements were reached in 1998 ($57 million), 116 federal and 15 state cases remain pending. Management does not expect a material adverse effect on financial position.
• Year 2000 (Y2K): Remediation costs are expected to approximate $100 million through the end of 1999, with one-third spent in 1999. Internal systems are compliant; business continuity plans are underway.
• Capital Resources: The company maintains AAA/Aa1 credit ratings with $2.505 billion in unused domestic lines of credit. It has the capacity to issue up to $1.35 billion in senior debt securities.

Investor Verification Checklist

• Verify the status of FDA approvals for Abbokinase and the timeline for resolving manufacturing concerns.
• Monitor the impact of generic Hytrin entry on the Pharmaceutical segment's revenue and margins in Q3 and Q4 1999.
• Confirm the closing dates and financial terms of the ALZA and Perclose acquisitions.
• Review updates on the 131 pending antitrust lawsuits and potential settlement costs.
• Assess the progress of Y2K remediation for third-party suppliers and embedded systems.